Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.69 |
| ▸ | F3 | P13726 | 1/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.64 |
| ▸ | PYGL | P06737 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NHERF1 | O14745 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30457940 | 0.88 | F7 (0.65) | F7F3NR4A2PYGLALDH1A1 | |
| SCHEMBL9788942 | 0.88 | F7 (0.65) | F7F3NR4A2PYGLALDH1A1 | |
| SCHEMBL3188134 | 0.88 | NR4A2 (0.64) | F7F3NR4A2HTR2AALDH1A1 | |
| SCHEMBL26261524 | 0.85 | NR4A2 (0.62) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL26261554 | 0.85 | NR4A2 (0.62) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL30457844 | 0.85 | NR4A2 (0.62) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL25259281 | 0.85 | NR4A2 (0.62) | F7F3NR4A2PYGLNHERF1 | |
| Hydrochloric Acid SCHEMBL25306279 | 0.84 | NR4A2 (0.60) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL25742072 | 0.82 | NR4A2 (0.58) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL5912617 | 0.82 | F7 (0.75) | F7F3NR4A2PYGLNHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | F7 4383/4885F3 4159/4885NR4A2 3646/4885 |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | BIRC7, BIRC5, BIRC2 | F7 4372/4885F3 3891/4885NR4A2 4003/4885 |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | BIRC7, BIRC5, BIRC2 | F7 4372/4885F3 3891/4885NR4A2 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.